Overview
Kintsugi Health builds voice biomarker technology that analyzes short speech clips to detect signs of depression and anxiety. Its system licenses this tool to risk-bearing health systems to integrate as an objective mental health screening aid alongside clinician judgment. The product processes audio through an AI model to generate risk indicators used in screening, monitoring, and intervention. The company differentiates itself through a strong focus on ethical AI, explainability, privacy, and regulatory compliance, aiming to make mental health care more scalable and equitable.
Work here?Claim your company
Simplify's take
What believers are saying
- Kintsugi open-sourced its models on February 10, 2026, accelerating third-party adoption.
- Its 2026 deepfake-detection findings broaden use cases beyond depression screening.
- Public recognition from Microsoft Pegasus and Forbes kept the science visible.
What critics are saying
- Kintsugi shut down commercial operations on February 10, 2026.
- Open-source Apache 2.0 licensing destroys pricing power and proprietary moats.
- FDA clearance never arrived, leaving buyers exposed to regulatory and liability risk.
What makes Kintsugi unique
- Kintsugi built clinically validated voice biomarkers from short free-form speech clips.
- Its API-first workflow embeds mental-health screening into telehealth, call centers, and RPM apps.
- It completed a long FDA De Novo path before shutting down commercial operations.
Help us improve and share your feedback! Did you find this helpful?
Funding
Notable Investors:
Series A funding typically happens when a startup has a product and some customers, and now needs funding to scale. This money is usually used to grow the team, expand marketing, and improve the product. Venture capital firms are frequently the main investors here.
Series A Funding Comparison
Industry standards
Ind Avg. $15M
$3.7M
$5M
$8.2M
$15M
$20M
$30M